Community Considerations in Relapsed/Refractory Multiple Myeloma: Current and Developing Anti-BCMA Therapies
Post-Test/Evaluation

Questions marked with a * are required
26%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Are you a Physician? 
GR is a 72-year-old male patient with multiple myeloma who is frustrated with therapy after receiving 3 prior lines of treatment and experienced relapse each time. He is not a candidate for stem cell transplant. He states that he had a brother with leukemia who was cured and wants to know why myeloma is so difficult to eradicate. Which of the following reasons is/are explanations of why multiple myeloma is a difficult hematologic malignancy to treat from the perspective of treatment resistance?
Which of the following treatments are common mechanisms of frontline management of multiple myeloma that are also used in the management of relapsed/refractory multiple myeloma? 
Which of the following most accurately describes the mechanism of BCMA-targeted bispecific antibodies in the management of relapsed/refractory multiple myeloma that has failed multiple prior regimens?
Powered by QuestionPro